Charles H. Reynolds
Email: creynolds@gfreebio.com, www.gfreebio.com

Experience

2011-present Founder, Gfree Bio, LLC

- Gfree Bio develops and delivers modeling, informatics, and structure-based design capabilities for emerging and established biotech companies. Gfree Bio has helped advance drug discovery programs for more than 60 companies since its founding.
- Critical expert witness for a successful patent settlement in excess of $1 billion.
- Principal Investigator for NIH STTR program (2016-2017) at Gfree Bio to develop new methodology for refining protein-ligand cocrystal structures.
- Acting CSO, PPI Mimics, LLC (2013-2015), and PI for two NIH grants.
- Other collaborations include: NIH SBIR The Wistar Institute; multiple NIH SBIRs Phelix Therapeutics; NIH STTR Fox Chase Chemical Diversity and Drexel College of Medicine, NIH SBIR for CerSci Therapeutics (acquired by Acadia).
- Co-inventor of phase III clinical candidate Resmetirom (Madrigal Pharmaceuticals).

2010-2011 Senior Director and Head of Discovery Technologies, Ansaris

- Responsible for scientific computing, proprietary discovery technology, structural biology, and IT. Member of senior management team with significant business development responsibilities.

- Initiated a major update of core computational fragment-based drug design platform. Refocused technology to target small molecule ligands for protein-protein interactions. Updated and improved software (speed, efficiency, user-interface).

- Leadership role in identification and prosecution of an internal target that led to a significant pharma partnering opportunity.

- Executive management of major research collaboration with Novartis.

2000-2010 Research Fellow, Johnson & Johnson Pharmaceutical R&D

- Responsibilities included managing modeling and informatics research teams at the Spring House, PA and La Jolla, CA sites. Managed significant hardware and software budgets across multiple US sites.

- Teams under my direction provided critical support for progression of tens of compounds to early development, multiple compounds to clinical development. Contributed to carisbamate NDA and European registration for Dacogen®.

- Led development of new discovery methodology at J&J including: informatics tools for fragment-based design, novel protocols for improved crystal-structure refinement, linear interaction energy approaches for ligand optimization, a similarity-based tool for scoring reagents for "drug-likeness," application of linear-scaling quantum calculations to analysis of protein structures, and structure-based ADME-Tox. The latter effort

includes a published multi-state homology model for the hERG channel that was employed successfully in multiple discovery programs and was honored in 2008 as a most cited article by Elsevier.

- Migrated J&J Computer-Aided Drug Discovery (CADD) groups to linux-based clusters and workstations, and consolidated CADD software licenses across sites. This effort resulted in a significant improvement in computational capabilities while reducing the overall cost of high-performance computing.

- Member of the New Targets Evaluation Committee for drug discovery. Organized a series of global J&J CADD and structural-biology meetings. Initiated external research collaborations at Penn State, Yale, and the University of Florida. Coordinated J&J's first structural-biology collaboration with an outside crystallography CRO.

1995-2000 Research Fellow, **1984-1994** Senior Scientist, Rohm and Haas (DowDuPont)

- Co-inventor of a new class of ergosterol biosynthesis inhibitor antifungals. Awarded the highest scientific award in the company (Otto Haas Award).

- Led an interdisciplinary team of a dozen scientists tasked with developing new drug therapies and diagnostic aids. This project resulted in a novel nanoparticle-based targeted contrast agent for MR imaging. Roles included developing the concept and selling it to R&D management, leading the team, establishing a collaboration with the University of Pennsylvania Medical School, and developing a market analysis in collaboration with Argonex (a biotechnology company acquired by Millipore).

2019-present Editorial Advisory Board, Journal Chemical Information and Modeling

2014-present Editorial Advisory Board, ACS Medicinal Chemistry Letters

2009-2013 Director (Industry Advisory Board) QuantumBio Inc.

2013 J.T. Oden Visiting Faculty Fellow, ICES, The University of Texas at Austin

2010-2017 Adjunct Professor, Pennsylvania Drug Discovery Institute

2008-2018 Member, American Chemical Society Publications Committee

2007-2016 NIH study sections, BDMA, BCMB, IMST-10, IMST-11, NCI ZCA1

2006-2011 Scientific Advisory Board, Keystone Symposia

2006-2009 Councilor, American Chemical Society

1998-2006 Editorial Advisory Board, Journal of Molecular Graphics and Modeling

1998 Joint postdoctoral research supervisor, University of North Carolina at Chapel Hill

1996-1998 Joint graduate research supervisor, The Pennsylvania State University

1990 Adjunct Professor, The University of Pennsylvania

Additional Experience and Leadership Activities

2015 National Academy of Sciences STTR program workshop; **2008** Co-organizer, first Keystone Symposium on computer-aided drug discovery; **2006-2009** Advisory Board for NSF sponsored science and math education initiative at Temple University (TU-SMART**); 2007** Co-organizer, ACS Prospectives Meeting, Advances in Structure-Based Drug Discovery; **2007** Inaugural Keck Foundation Lecture, St. Edward's University**; 2007** Lecturer, ACS computational chemistry short course**; 2005** Organizer, ACS Prospectives Meeting, Advances in Structure-Based Drug Discovery; **1999-2000** Rohm and Haas Technology Center Coordinator for Life Sciences; **1998-2000** Membership Committee, ACS Computers in Chemistry Division; **1999** Co-taught a computational chemistry short course (Jan Term) at Austin College; **1997** Chair, ACS Computers in Chemistry Division; **1991-1995** Treasurer, ACS Computers in Chemistry Division; **1989** Faculty, QCPE course.

Education

1984 Ph.D. in Theoretical Organic Chemistry, The University of Texas at Austin, Austin, Texas. Supervisor: Michael J.S. Dewar.

1979 B.A. in Chemistry, Austin College, Sherman, Texas. Honors in Chemistry.

Management Training

2013 Kauffman Institute Entrepreneur Training Program

2002 Johnson & Johnson Management Fundamentals

2001 Johnson & Johnson Manager and the Law

1993 First-Line Leadership

1992 The Leadership Challenge

Awards

2015 Gfree Bio selected as a Kauffman Foundation FastTrac success story

2012 Distinguished Alumni Award, Austin College

2010 Fellow of the American Chemical Society

2007 Standards of Leadership Award, Johnson & Johnson

2007 Platinum Encore Award, Johnson & Johnson (Dacogen registration in Europe)

2000 Johnson & Johnson Excellence in Science Award (four awarded company wide)

1987 Otto Haas Award, Rohm and Haas (highest award for scientific achievement).

1993 Marion Cox Award, Austin College; **1984** University of Texas Career Development Award; **1983** Robert A. Welch Foundation Pre-doctoral Fellowship, The University of Texas at Austin; **1978** P.S. Wharton Fellowship in chemistry, Austin College; **1978** National Science Foundation Undergraduate Research Scholarship, The University of Texas at Arlington; **1975-1979** Robert A. Welch Undergraduate Chemistry Scholarship.

Publications

Author of over 100 papers, chapters, books, and patents

Publications

Bratkowski, M.; Burdett, T.C.; Danao, J.; Wang, X.; Mathur, P.; Gu, W.; Beckstead, J.; Talreja, S.; Yang, Y.-S.; Danko, G.; Park, J.H.; Walton, M.; Brown, S.P.; Tegley, C.M.; Joseph, P.R.B.; Reynolds, C.H.; Sambashivan, S. **Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in Preclinical models of nerve injury and disease,** Neuron, 2022, https://doi.org/10.1016/j.neuron.2022.08.017

Carta, L.; Hutcheson, R.; Davis, S.A.; Rudolph, M.J.; Reynolds, C.H.; Quick, M.; Williams, T.M.; Schmertzler, M.; Hadari, Y.R. **Developing small molecules that inhibit K-Ras/GTP binding based on new affinity measurements**, bioRxiv, 2020, doi: https://doi.org/10.1101/2020.07.27.218248

Agragiotis, D.K.; Holloway, M.K.; Johnson, S.A.; Reynolds, C.H; Stouch, T.R.; Tropsha, A.; Waller, C.L. **Chemistry, information, and Frank: a tribute to Frank Brown**, J. Computer-Aided Molecular Design, 2018, 32, 723-729. https://doi.org/10.1007/s10822-018-0135-9

Reynolds, C.H. **In this issue**, ACS Med. Chem. Letters, 2018, 65-66.

Reynolds, C.H.; Reynolds, R.C. **Group additivity in ligand binding affinity: An alternative approach to ligand efficiency** J. Chem. Inf. Model, 2017, 57, 3086-3093 DOI: 10.1021/acs.jcim.7b00381

Reynolds, Charles H. **Ligand efficiency metrics: why all the fuss?** Future Med. Chem. 2015, 7, 1363-1365.

Reynolds, Charles H., **Protein-ligand cocrystal structures: We can do better**, ACS Medicinal Chemistry Letters, 2014. (one of the most read papers in ACS Medicinal Chemistry Letters 2014)

Murray, Christopher W., Daniel A. Erlanson, Andrew L. Hopkins, György M. Keserü, Paul D. Leeson, David C. Rees, Charles H. Reynolds, and Nicola J. Richmond. **Validity of Ligand Efficiency Metrics**. ACS Medicinal Chemistry Letters (2014) 5, 2-5. (One of the most read papers in ACS Medicinal Chemistry Letters 2014)

Martha J. Kelly, Charles H. Reynolds, et al. **Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia,** Journal of Medicinal Chemistry, 2014, 57, 3912-3923. DOI: 10.1021/jm4019299

Hopkins, A.L.; Keseru, G.M.; Leeson, P.D.; Rees, D.C.; Reynolds, C.H. **The role of ligand efficiency measures in drug discovery**, Nature Reviews Drug Discovery, 2014, 13, 105-121.

Reynolds, Charles, H., **Impact of computational structure-based methods on drug discovery**, Current Pharmaceutical Design, 2014, 20, 3380-3386. DOI: 10.2174/13816128202014052810553 2

Reynolds, Charles H.; Holloway, M. Katharine, **Thermodynamics of ligand binding and efficiency**, ACS Medicinal Chemistry Letters, (2011) 2, 433-437. *One of the top ten accessed papers in ACS Medicinal Chemistry Letters and the Journal of Medicinal Chemistry for 2011and 2012.*

Céline Schalk-Hihi, Carsten Schubert, Richard Alexander, Shariff Bayoumy, Jose C. Clemente, Ingrid Deckman, Renee L. DesJarlais, Keli C. Dzordzorme, Christopher M. Flores, Bruce Grasberger, James K. Kranz, Frank Lewandowski, Li Liu, Hongchang Ma, Diane Maguire, Mark J. Macielag, Mark E. McDonnell, Tara Mezzasalma Haarlander, Robyn Miller, Cindy Milligan, Charles Reynolds, Lawrence C. Kuo, **Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution** Protein Science (April 2011) 20, 670–683.

Klon, Anthony E.; Konteatis, Zenon; Meshkat, Siavash N.; Zou, Jinming; Reynolds, Charles H. **Fragment**

and protein simulation methods in fragment based drug discovery, Drug Devel. Res. (2011) 72, 1-8.

Yifang Huang, Eric D. Strobel, Chih Y. Ho, Charles H. Reynolds, Kelly A. Conway, Jennifer A. Piesvaux, Douglas E. Brenneman, George J. Yohrling, H. Moore Arnold, Daniel Rosenthal, Richard S. Alexander, Brett A. Tounge, Marc Mercken, Marc Vandermeeren, Michael H. Parker, Allen B. Reitz, Ellen W. Baxter, **Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads**, Bioorganic & Medicinal Chemistry Letters, Volume 20, Issue 10, 15 May 2010, Pages 3158-3160.

Merz, Kenneth M.; Ringe, Dagmar; Reynolds, Charles H., Editors, **Drug design: ligand and structure based approaches**, Cambridge University Press, 2010.

Reynolds, Charles H. **Computer-aided drug design: A practical guide to protein-structure based modeling,** published in Drug design: ligand and structure based approaches, Cambridge University Press, K. M. Merz, D. Ringe, and C. H. Reynolds, editors, 2010.

Zhang, Xiaohua; Gibbs, Alan C.; Reynolds, Charles H.; Peters, Martin B.; Westerhoff, Lance M. **Quantum Mechanical Pairwise Decomposition Analysis of Protein Kinase B Inhibitors: Validating a New Tool for Guiding Drug Discovery**. J. Chem. Inf. Model. (2010), 50, 651-661.

Lawson, Edward C.; Luci, Diane K.; Ghosh, Shyamali; Kinney, William A.; Reynolds, Charles H.; Qi, Jenson; Smith, Charles E.; Wang, Yuanping; Minor, Lisa K.; Haertlein, Barbara J.; Parry, Tom J.; Damiano, Bruce P.; Maryanoff, Bruce E. **Nonpeptide Urotensin-II Receptor Antagonists: A New Ligand Class Based on Piperazino-Phthalimide and Piperazino-Isoindolinone Subunits.** Journal of Medicinal Chemistry (2009), 52, 7432-7445.

Li, Jian; Reynolds, C. H. **A quantum mechanical approach to ligand binding: Calculation of ligand-protein binding affinities for stromelysin-1 (MMP-3) inhibitors**, Canadian Journal of Chemistry, (2009), 87, 1480-1484.

Reitz, Allen B.; Smith, Garry R.; Tounge, Brett A.; Reynolds, Charles H. **Hit Triage Using Efficiency Indices after Screening Compound Libraries in Drug Discovery.** Current Topics in Medicinal Chemistry (2009), 9, 1718-1724.

Bembenek, Scott D.; Tounge, Brett A.; Reynolds, Charles H.. **Ligand efficiency and fragment-based drug discovery.** Drug Discovery Today (2009), 14(5/6), 278-283.

Reynolds, Charles H.; Tounge, Brett A.; Bembenek, Scott D. **Ligand binding efficiency: trends, physical basis, and implications.** Journal of Medicinal Chemistry (2008), 51(8), 2432-2438.

Baxter, Ellen W.; Conway, Kelly A.; Kennis, Ludo; Bischoff, Francois; Mercken, Marc H.; De Winter, Hans L.; Reynolds, Charles H.; Tounge, Brett A.; Luo, Chi; Scott, Malcolm K.; Huang, Yifang; Braeken, Mirielle; Pieters, Serge M. A.; Berthelot, Didier J. C.; Masure, Stefan; Bruinzeel, Wouter D.; Jordan, Alfonzo D.; Parker, Michael H.; Boyd, Robert E.; Qu, Junya; Alexander, Richard S.; Brenneman, Douglas E.; Reitz, Allen B. **2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β -site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead.** Journal of Medicinal Chemistry (2007), 50(18), 4261-4264. *One of the most accessed articles in JMC for 2007*.

Reynolds, Charles H.; Bembenek, Scott D.; Tounge, Brett A. **The role of molecular size in ligand efficiency.** Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4258-4261.

Li, Jian; Rajamani, Ramkumar; Tounge, Brett A.; Reynolds, Charles H.. **Mechanistic modeling in drug discovery: MMP-3 and the HERG channel as examples.** Modelling Molecular Structure and Reactivity in Biological Systems, Kevin J. Naidoo, John B. Brady, Martin J. Field, Jiali Gao, and Michael Hahn Editors, The Royal Society of Chemistry (2006) 283-288.

Yu, Ning; Hayik, Seth A.; Wang, Bing; Liao, Ning; Reynolds, Charles H.; Merz, Kenneth M., Jr. **Assigning the Protonation States of the Key Aspartates in β -Secretase Using QM/MM X-ray Structure Refinement.** Journal of Chemical Theory and Computation (2006), 2(4), 1057-1069.

Reynolds, Charles H.; Editor. **Special Issue: Understanding Protein-Ligand Interactions. (Papers from 2005 National ACS Meeting held in San Diego, California.) [In: J. Mol. Graphics Modell.; 2006, 24(6)].** (2006), 74 pp.

Tounge, Brett A.; Rajamani, Ramkumar; Baxter, Ellen W.; Reitz, Allen B.; Reynolds, Charles H.. **Linear interaction energy models for β -secretase (BACE) inhibitors: Role of van der Waals, electrostatic, and continuum-solvation terms.** Journal of Molecular Graphics & Modelling (2006), 24(6), 475-484.

Reynolds, Charles H. **Understanding protein-ligand interactions.** Journal of Molecular Graphics & Modelling (2006), 24(6), 413.

Li, Jian; Rajamani, Ramkumar, Tounge, Brett A.; Reynolds, Charles H. **Mechanistic modeling in drug discovery: MMP-3 and the hERG channel as examples**, in Modeling Molecular Structure and Reactivity in Biological Systems, Kevin J. Naidoo, John Brady, Martin J. Field, Jiali Gao, and Michael Hann, Editors, 2015 RSC Publishing, Cambridge, UK, pages 283-288.

Rajamani, Ramkumar; Tounge, Brett A.; Li, Jian; Reynolds, Charles H.. **A two-state homology model of the hERG K+ channel: application to ligand binding.** Bioorganic & Medicinal Chemistry Letters (2005), 15(6), 1737-1741. *Elsevier top 25 most accessed article in 2005. Most highly cited 2005-2008.*

Rajamani, Ramkumar; Reynolds, Charles H. **Modeling the Protonation States of the Catalytic Aspartates in β -Secretase.** Journal of Medicinal Chemistry (2004), 47(21), 5159-5166.

Rajamani, Ramkumar; Reynolds, Charles H. **Modeling the binding affinities of β -secretase inhibitors: application to subsite specificity.** Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4843-4846.

Bembenek, Scott D.; Tounge, Brett A.; Coats, Steven J.; Reynolds, Charles H. **A Web-based chemoinformatics system for drug discovery.** Methods in Molecular Biology (Totowa, NJ, United States) (2004), 275(Chemoinformatics), 65-84.

Tounge, Brett A.; Reynolds, Charles H.. **Defining Privileged Reagents Using Subsimilarity Comparison.** Journal of Chemical Information and Computer Sciences (2004), 44(5), 1810-1815.

Matthews, Jay M.; Hoekstra, William J.; Dyatkin, Alexey B.; Hecker, Leonard R.; Hlasta, Dennis J.; Poulter, Brenda L.; Andrade-Gordon, Patricia; de Garavilla, Lawrence; Demarest, Keith T.; Ericson, Eric; Gunnet, Joseph W.; Hageman, William; Look, Richard; Moore, John B.; Reynolds, Charles H.; Maryanoff, Bruce E. **Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.** Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2747-2752.

Lee, Jung; Reynolds, Charles; Jetter, Michele C.; Youngman, Mark A.; Hlasta, Dennis J.; Dax, Scott L.; Stone, Dennis J.; Zhang, Sui-Po; Codd, Ellen E. **Design and synthesis of novel pyrrolidine-containing bradykinin antagonists.** Bioorganic & Medicinal Chemistry Letters (2003), 13(11), 1879-1882.

Tounge, Brett A.; Reynolds, Charles H.. **Calculation of the binding affinity of β -secretase inhibitors using the linear interaction energy method.** Journal of Medicinal Chemistry (2003), 46(11), 2074-2082.

Chen, Xin; Reynolds, Charles H.. **Performance of Similarity Measures in 2D Fragment-Based Similarity Searching: Comparison of Structural Descriptors and Similarity Coefficients.** Journal of

Chemical Information and Computer Sciences (2002), 42(6), 1407-1414.

Tounge, Brett A.; Pfahler, Lori B.; Reynolds, Charles H.. **Chemical information based scaling of molecular descriptors: A universal chemical scale for library design and analysis.** Journal of Chemical Information and Computer Sciences (2002), 42(4), 879-884.

Tropsha, Alexander; Reynolds, Charles H.. **Designing Focused Libraries for Drug Discovery: Hit to Lead to Drug.** Journal of Molecular Graphics & Modelling (2002), 20(6), 427-428.

Creighton, Christopher J.; Reynolds, Charles H.; Lee, Daniel H. S.; Leo, Gregory C.; Reitz, Allen B. **Conformational Analysis of the Eight-Membered Ring of the Oxidized Cysteinyl-Cysteine Unit Implicated in Nicotinic Acetylcholine Receptor Ligand Recognition.** Journal of the American Chemical Society (2001), 123(50), 12664-12669.

Reynolds, Charles H.; Tropsha, Alexander; Pfahler, Lori B.; Druker, Ross; Chakravorty, Subhas; Ethiraj, G.; Zheng, Weifan. **Diversity and coverage of structural sublibraries selected using the SAGE and SCA algorithms.** Journal of Chemical Information and Computer Sciences (2001), 41(6), 1470-1477.

Cheng, A.; Best, S. A.; Merz, K. M.; Reynolds, C. H.. **GB/SA water model for the Merck molecular force field (MMFF).** Journal of Molecular Graphics & Modelling (2000), 18(3), 273-282.

Reynolds, Charles H.; Annan, Nikoi; Beshah, Kebede; Huber, Jon H.; Shaber, Steven H.; Lenkinski, Robert E.; Wortman, Jeffrey A. **Gadolinium-Loaded Nanoparticles: New Contrast Agents for Magnetic Resonance Imaging.** Journal of the American Chemical Society (2000), 122(37), 8940-8945.

Chakravorty, S.; Reynolds, C. H.. **Improved AMBER torsional parameters for the N-N rotational barrier in diacylhydrazines.** Journal of Molecular Graphics & Modelling (2000), Volume Date 1999, 17(5/6), 315-324.

Reynolds, Charles H.. **Designing Diverse and Focused Combinatorial Libraries of Synthetic Polymers.** Journal of Combinatorial Chemistry (1999), 1(4), 297-306.

Best, Scott A.; Merz, Kenneth M. Jr.; Reynolds, Charles H.. **Free Energy Perturbation Study of Octanol/Water Partition Coefficients: Comparison with Continuum GB/SA Calculations.** Journal of Physical Chemistry B (1999), 103(4), 714-726.

Reynolds, Charles H.; Best, Scott A. **A fast molecular simulation to calculate lipophilicity.** CHEMTECH (1998), 28(11), 28-34.

Reynolds, Charles H.; Druker, Ross; Pfahler, Lori B. **Lead Discovery Using Stochastic Cluster Analysis (SCA): A New Method for Clustering Structurally Similar Compounds.** Journal of Chemical Information and Computer Sciences (1998), 38(2), 305-312.

Reynolds, Charles H. **Semiempirical MO methods: the middle ground in molecular modeling.** THEOCHEM (1997), 401(3), 267-277.

Best, Scott A.; Merz, Kenneth M., Jr.; Reynolds, Charles H.. **GB/SA-Based Continuum Solvation Model for Octanol.** Journal of Physical Chemistry B (1997), 101(49), 10479-10487.

Reynolds, Charles H.. **Molecular modeling in agrochemicals.** Chemistry & Industry (London) (1997), (15), 592-595.

Reynolds, Charles H.; Hormann, Robert E. **Theoretical Study of the Structure and Rotational Flexibility of Diacylhydrazines: Implications for the Structure of Nonsteroidal Ecdysone Agonists**

and Azapeptides. Journal of the American Chemical Society (1996), 118(39), 9395-9401.

Reynolds, Charles H.. **Estimating Lipophilicity Using the GB/SA Continuum Solvation Model: A Direct Method for Computing Partition Coefficients.** Journal of Chemical Information and Computer Sciences (1995), 35(4), 738-42.

Chaubal, Mahesh V.; Payne, Gregory F.; Reynolds, Charles H.; Albright, Robert L. **Equilibria for the adsorption of antibiotics onto neutral polymeric sorbents: experimental and modeling studies.** Biotechnology and Bioengineering (1995), 47(2), 215-26.

Reynolds, Charles H.; Holloway, M. Katharine; Cox, Harold K.; Editors. **Computer-Aided Molecular Design: Applications in Agrochemicals, Materials, and Pharmaceuticals. (Dev. from a Symp. Sponsored by the Div. of Computers in Chem. and the Div. of Agrochemicals at the 207th National Meeting of the ACS, San Diego, California, March 13-17, 1994. [In: ACS Symp. Ser., 1995; 5898].** (1995), 428 pp. CAN 123:55040 AN 1995:584021

Reynolds, Charles H.; Shaber, Steven H. **Rational design of novel ergosterol biosynthesis inhibitor fungicides.** ACS Symposium Series (1995), 589(Computer-Aided Molecular Design), 171-82 2 Plates - pp. 230a-230b.

Reynolds, Charles H.. **Combined Molecular Orbital and Group Additivity Approach for Modeling Thermochemical Properties: Application to Hydrazides.** Journal of Chemical Information and Computer Sciences (1994), 34(3), 671-5.

Reynolds, Charles H.. **Hydride affinities of halogen substituted carbocations: the C2H4X+ (X = fluorine, chlorine and bromine) cations.** THEOCHEM (1992), 259 257-63.

Reynolds, Charles H.. **Structure and relative stability of halogenated carbocations: the C2H4X+ and C4H8X+ (X = fluoro, chloro, bromo) cations.** Journal of the American Chemical Society (1992), 114(22), 8676-82.

Reynolds, Charles H. **Book Review of Reviews in Computational Chemistry, Vol. I**, J. Am. Chem. Soc. 1992, 114, 5484.

Reynolds, Charles H. **Book Review of Reviews in Computational Chemistry, Vol. II** J. Am. Chem. Soc. 1992, 114, 5484.

Reynolds, Charles H.. **Trihalomethyl cations: relative stability of CX3+ (X = F, Cl or Br).** Journal of the Chemical Society, Chemical Communications (1991), (14), 975-6.

Reynolds, Charles H.. **Relative stabilities of isomeric chlorine-substituted carbocations: the C2H4Cl+ cation.** Journal of the Chemical Society, Chemical Communications (1990), (21), 1533-5.

Reynolds, Charles H.. **Methyl chloride-formic acid van der Waals complex: a model for carbon as a hydrogen bond donor.** Journal of the American Chemical Society (1990), 112(22), 7903-8.

Frederick, Clay B.; Reynolds, Charles H.. **Modeling the reactivity of acrylic acid and acrylate anion with biological nucleophiles.** Toxicology Letters (1989), 47(3), 241-7.

Holloway, M. Katharine; Reynolds, Charles H.; Merz, Kenneth M., Jr. **An ab initio investigation of the double proton shift in azophenine.** Journal of the American Chemical Society (1989), 111(9), 3466-8.

Fujimoto, Ted. T.; Reynolds, Charles H. **Rohm and Haas Scientists Apply CAMD Techniques to Fungicide Design** Chemical Design and Automation News, July, 1988

Reynolds, Charles H.. **An AM1 theoretical study of the structure and electronic properties of porphyrin.** Journal of Organic Chemistry (1988), 53(26), 6061-4.

Merz, Kenneth M., Jr.; Reynolds, Charles H.. **Tautomerism in free base porphyrins. The porphyrin potential energy surface.** Journal of the Chemical Society, Chemical Communications (1988), (2), 90-2.

Reynolds, Charles H. **Modeling of shape/size selective separations: AM1 rotational barriers for some substituted benzenes.** THEOCHEM (1988) 40 79-88. Invited paper, symposium in print in honor of M.J. S. Dewar's 70th birthday.
Reynolds, Charles H.; Frederick, Clay B. **Calculations on the Reactivity of Biological Nucleophiles** Toxicologist, 1988, 8, 52.

Lynn, Lee L.; Pierce, Thomas H.; Reynolds, Charles H. **AMPAC: Version for IBM Mainframe Computers** QCPE Bull. 1987, 7, 37.

Reynolds, Charles H.; Pierce, Thomas H. **AMPAC (Apollo Version)** QCPE Bull. 1986, 6, 95.

Dewar, Michael J. S.; Reynolds, Charles H. **A MINDO/3 study of the ethylene dication.** THEOCHEM (1986), 29(3-4), 209-14.

Dewar, Michael J. S.; Reynolds, Charles H.. **An improved set of MNDO parameters for sulfur.** Journal of Computational Chemistry (1986), 7(2), 140-3.

Reynolds, Charles Howard. **Theoretical studies of organic reaction mechanisms using MNDO and MINDO/3.** (1984), 204 pp. CAN 104:129182 AN 1986:129182

Pomerantz, Martin; Dassanayake, Nissanke L.; McManus, Timothy R.; Reynolds, Charles H.. **Thermal reorganizations of 1,2:3,4-dibenzotropilidene (5H-dibenzo[a,c]cycloheptene), 7,7'-bi(1,2:3,4-dibenzotropyl) [5,5'-bi(5H-dibenzo[a,c]cycloheptenyl)], and the 1,2:3,4-dibenzotropyl (dibenzo[a,c]cycloheptenyl) free radical.** Journal of Organic Chemistry (1984), 49(21), 4029-32.

Dewar, Michael J. S.; Reynolds, Charles H. **Ground states of molecules. 68. The C4H7+ potential surface.** Journal of the American Chemical Society (1984), 106(21), 6388-92.

Dewar, Michael J. S.; Reynolds, Charles H. **Ground states of molecules. 64. π -Complexes as intermediates in reactions. Biomimetic cyclization.** Journal of the American Chemical Society (1984), 106(6), 1744-50.

Dewar, Michael J. S.; Ford, George P.; Reynolds, Charles H.. **Ground states of molecules. 61. Relative stabilities of o-, m-, and p-benzyne.** Journal of the American Chemical Society (1983), 105(10), 3162-7.

Dewar, Michael J. S.; Reynolds, Charles H. **Tritium migration in tritiated anisole.** Journal of the American Chemical Society (1982), 104(11), 3244-6.

Patents

Hadari, Y., Luca, C., Schmertzler, M., Williams, T., Reynolds, C., Hutcheson, R. SHY Therapeutics LLC, **Compounds that interact with the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease**, United States patent US11,026,930, April 13, 2020.

Hadari, Y., Luca, C., Schmertzler, M., Williams, T., Reynolds, C., Hutcheson, R. SHY Therapeutics LLC, **Compounds that interact with the RAS superfamily for the treatment of cancers,**

inflammatory diseases, rasopathies, and fibrotic disease, United States patent US10,588,894, March 17, 2020.

Taub R, Reynolds CH, Shu, L., Wang, P., Choi, D.S., inventors; Madrigal Pharmaceuticals Inc, assignee. **Methods of synthesizing thyroid hormone analogs and polymorphs thereof.** United States patent US 10,376,517 B2. 2019 Aug. 13.

Taub R, Reynolds CH, inventors; Madrigal Pharmaceuticals Inc, assignee. **Method of synthesizing thyroid hormone analogs and polymorphs thereof.** United States patent US 9,968,612. 2018 May 15.

Hadari, Yaron R., Luca Carta, Michael Schmertzler, Theresa M. Williams, and Charles H. Reynolds. **Compounds for the treatment of cancer and inflammatory disease**. U.S. Patent US 10,221,191 B2, Mar. 5, 2019.

Keenan, R., Reynolds, C., Whittaker, B., Kight, L., Sutton, J., Hydn, G., Maly, D., OptiKira, **Compounds and compositions for IRE1 inhibition**, US 62/553,320, filed Sep. 1, 2017.

D. Keith Hester, Robert J. Duguid, Martha Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Rebecca Taub, Charles H. Reynolds, Duk Soon Choi, Lianhe Shu, Ping Wang **Method of synthesizing thyroid hormone analogs and polymorphs thereof,** Madrigal Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., PCT/US2013/060177, Mar 20, 2014.

Baxter, Ellen, Robert Boyd, Steve Coats, Alfonzo Jordan, Allen Reitz, Charles H. Reynolds, Malcolm Scott, and Mark Schulz. "**NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE (BACE**)." European Patent EP 1776350, issued January 23, 2013.

Baxter, Ellen, Robert Boyd, Steven J. Coats, Alfonzo D. Jordan, Allen B. Reitz, Charles H. Reynolds, Mark Schulz, and Malcolm Scott. "**2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE).**" U.S. Patent 8,426,429, issued April 23, 2013.

Baxter, Ellen, Bischoff, Francois Paul, Boyd, Robert E., Braeken, Mirielle, Coats, Steve, Huang, Yifang, Jordan, Alfonzo D., Luo, Chi, Mercken, Marc Hubert, Pieters, Serge Maria Aloysius, Reitz, Allen B., Reynolds, Charles H., Ross, Tina Morgan, Tounge, Brett A., Schulz, Mark J., De Winter, Hans Louis Jos **2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)** United States Jansssen Pharmaceutica N.V. (Beerse, BE) Issued 02/26/2013, US. Patent 8,383,637.

Baxter, Ellen, Christopher J. Creighton, Tianbao Lu, Allen B. Reitz, Charles H. Reynolds, Tina Morgan Ross, and Ellen Sieber-McMaster. **6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE).** U.S. Patent 8,076,358, issued December 13, 2011.

Baxter, Ellen, W. ; Reitz, Allen, B. ; Parker, Michael, H. ; Huang, Yifang ; Ho, Chih, Yung ; Strobel, Eric, D. ; Reynolds, Charles, H. **MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE),** Issued April 26, 2011, US 7,932,261 B2

Reitz, Allen B., Chi Luo, Yifang Huang, Tina M. Ross, Ellen E. Baxter, Brett A. Tounge, Michael H. Parker, Eric D. Strobel, and Charles H. Reynolds. **2-AMINO-3, 4-DIHYDRO-PYRIDO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE).** European Patent EP 1966198, issued March 16, 2011.

Baxter, Ellen, Allen B. Reitz, Umar Saibu Mohomed Maharoof, Yifang Huang, Christopher John Creighton, Charles H. Reynolds, Chi Luo, Brett A. Tounge, Tina Morgan Ross, and Tianbao Lu. **2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE).** U.S. Patent 7,868,022, issued January 11, 2011.

Baxter, Ellen ; Reitz, Allen B. ; Maharoof, Umar Saibu Mohomed ; Huang, Yifang ; Creighton, Christopher John ; Reynolds, Charles H. ; Luo, Chi ; Tounge, Brett A. ; Ross, Tina Morgan ; Lu, Tianbao **2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)** Issued August 31, 2010, US 7,786,116 B2

Baxter, Ellen E. ; Creighton, Christopher John ; Huang, Yifang ; Luo, Chi ; Parker, Michael H. ; Reitz, Allen B. ; Reynolds, Charles H. ; Ross, Tina Morgan ; Strobel, Eric D. ; Tounge, Brett A. **2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (BACE)** Issued May 12, 2009, US7,531,545 B2

BAXTER, Ellen, Christopher J. CREIGHTON, Tianbao LU, Allen B. REITZ, Charles H. REYNOLDS, Tina MORGAN ROSS, and Ellen SIEBER-MCMASTER. **2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE).** WIPO Patent WO/2009/097401, issued August 6, 2009.

BAXTER, Ellen ; REITZ, Allen B. ; HUANG, Yifang ; CREIGHTON, Christopher John ; MAHAROOF, Umar Saibu Mohomed ; REYNOLDS, Charles H. ; LUO, Chi ; TOUNGE, Brett A. ; ROSS, Tina Morgan ; LU, Tianbao **2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) Application No.** WO2007US61704A, **Filed:**20070206 , **Published:** 20071108 **WO2007092854 A3**

Baxter, Ellen; Reitz, Allen B.; Parker, Michael H.; Huang, Yifang; Ho, Chih Y.; Strobel, Eric D.; Reynolds, Charles H.. **Preparation of macrocycle derivatives as BACE inhibitors.** PCT Int. Appl. (2007), 84pp. CODEN: PIXXD2 WO 2007092839 A2 20070816 CAN 147:277629 AN 2007:912305

Baxter, Ellen; Reitz, Allen B.; Huang, Yifang; Creighton, Christopher John; Maharoof, Umar Saibu Mohomed; Reynolds, Charles H.; Luo, Chi; Tounge, Brett A.; Ross, Tina Morgan; Lu, Tianbao. **Preparation of 2-aminoquinolines as inhibitors of β -secretase (BACE).** PCT Int. Appl. (2007), 137pp. CODEN: PIXXD2 WO 2007092854 A2 20070816 CAN 147:277463 AN 2007:912298

Reitz, Allen B.; Luo, Chi; Huang, Yifang; Ross, Tina M.; Baxter, Ellen E.; Tounge, Brett A.; Parker, Michael H.; Strobel, Eric D.; Reynolds, Charles H.. **Preparation of 2-amino-3,4-dihydropyrido[3,4-d]pyrimidines as inhibitors of β -secretase (BACE).** PCT Int. Appl. (2007), 209pp. CODEN: PIXXD2 WO 2007050612 A1 20070503 CAN 146:482084 AN 2007:484212

BAXTER, Ellen ; BOYD, Robert ; COATS, Steve ; JORDAN, Alfonzo ; REITZ, Allen ; REYNOLDS, Charles H. ; SCOTT, Malcolm ; SCHULZ, Mark ; DE WINTER, Hans Louis Jos **NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE (BACE) Application No.** EP2005786778A, **Filed:**20050808 , **Published:** 20070425 **EP1776350 A1**

BAXTER, Ellen ; BISCHOFF, Francois, Paul ; BOYD, Robert ; BRAEKEN, Mirielle; COATS, Steven; HUANG, Yifang ; JORDAN, Alfonzo ; LUO, Chi ; MERCKEN, Marc, Hubert ; REYNOLDS, Charles, H. ; ROSS, Tina, Morgan ; TOUNGE, Brett, A. ; SCHULZ, Mark ; DE WINTER, Hans, Louis, Jos ; PIETERS, Serge Maria Aloysius ; REITZ, Allen, B. **2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) Application No.** EP2005785256A, **Filed:**20050808 , **Published:** 20070425 **EP1776349 A2**

Baxter, Ellen; Bischoff, Francois Paul; Boyd, Robert; Braeken, Mirielle; Coats, Steven; Huang, Yifang; Jordan, Alfonzo; Luo, Chi; Mercken, Marc Hubert; Reynolds, Charles H.; Ross, Tina Morgan; Tounge, Brett A.; Schulz, Mark; De Winte, Hans Louis Jos; Pieters, Serge Maria Aloysius; Reitz, Allen B. **Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β -secretase for treating Alzheimer's disease and related disorders.** PCT Int. Appl. (2006), 385 pp. CODEN: PIXXD2 WO 2006017836 A2 20060216 CAN 144:254142 AN 2006:152738

Baxter, Ellen; Boyd, Robert; Coats, Steve; Jordan, Alfonzo; Reitz, Allen; Reynolds, Charles H.; Scott, Malcolm; Schulz, Mark; De Winter, Hans Louis Jos. **Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β -secretase for treating Alzheimer's disease and related disorders.** PCT Int. Appl. (2006), 382 pp. CODEN: PIXXD2 WO 2006017844 A1 20060216 CAN 144:254141 AN 2006:149827

BAXTER, Ellen ; BISCHOFF, Francois, Paul ; BOYD, Robert ; BRAEKEN, Mirielle; COATS, Steven; HUANG, Yifang ; JORDAN, Alfonzo ; LUO, Chi ; MERCKEN, Marc, Hubert ; REYNOLDS, Charles, H. ; ROSS, Tina, Morgan ; TOUNGE, Brett, A. ; SCHULZ, Mark ; DE WINTER, Hans, Louis, Jos ; PIETERS, Serge Maria Aloysius ; REITZ, Allen, B. **2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) Application number**: 11/197,669 **Publication number**: US 2006/0079687 A1 **Filing date**: Aug 4, 2005

Annan, Nikoi; Reynolds, Charles H.; Shaber, Steven H.; Langenmeyr, Eric J. **Contrast Enhancing Agent Having a Polymeric Core and Polymeric Shell,** August 7, 2001, US Patent 6270748 B1

Annan, Nikoi ; Reynolds, Charles Howard ; Shaber, Steven Howard ; Langenmayr, Eric Jon **Polymeric MRI Contrast agents EP1031354 A3 Application No.** EP2000300091A, **Filed:**20000107, **Published:** 20030205

NIKOI ANAN ; REYNOLDS CHARLES HOWARD ; SHABER STEVEN HOWARD; LANGENMAYR ERIC JON **CONTRAST ENHANCING AGENT Application No.** JP20009851A, **Filed:**20000119 , **Published:** 20000802 **JP2000212101 A**

Shaber, Steven Howard ; Reynolds, Charles Howard ; Szapacs, Edward Michael **Silyl heterocyclic fungicides Application No.** EP1995301711A, **Filed:**19950315 , **Published:** 19971008 **EP672672 A3**

Shaber, Steven H.; Szapacs, Edward M.; Reynolds, Charles H. **Heterocylicacetonitriles and Fungicidal Use** Issued January 16, 1996, US 5,484,787

Shaber, Steven H.; Szapacs, Edward M.; Reynolds, Charles H. **Heterocylicacetonitriles and Fungicidal Use** Issued March 14, 1995, US 5,397,793

Shaber, Steven Howard; Reynolds, Charles Howard; Szapacs, Edward Michael. **Preparation of heterocyclic silyl derivatives as fungicides.** Issued September 19, 1995, US 5,451,563

Shaber, Steven Howard; Reynolds, Charles Howard; Szapacs, Edward Michael. **Preparation of heterocyclic silyl derivatives as fungicides.** Eur. Pat. Appl. (1995), 16 pp. CODEN: EPXXDW EP 672672 A2 19950920 CAN 124:23911 AN 1995:986358

Shaber, Steven Howard; Szapacs, Edward Michael; Reynolds, Charles Howard **Heterocyclicacetonitriles and their fungicidal use Application No.** EP1991301972A, **Filed:**19910308 , **Published:** 19941228 **EP451948 B1**

Shaber, Steven Howard; Szapacs, Edward Michael; Reynolds, Charles Howard. **Preparation of 2-heterocyclyl-2,ω -diphenylalkanenitriles as agrochemical fungicides.** Eur. Pat. Appl. (1991), 23 pp. CODEN: EPXXDW EP 451948 A1 19911016 CAN 116:21075 AN 1992:21075

Shaber, Steven Howard ; Sharma, Ashok Kumar ; Reynolds, Charles Howard **(2-Cyano-2-(phenyl or naphthyl)-2-substituted-ethyl) pyrazines, pyrimidines and pyridazines Application No.** EP1988300222A, **Filed:**19880112 , **Published:** 19910403 **EP276920 B1**

Shaber, Steven Howard ; Sharma, Ashok Kumar ; Reynolds, Charles Howard **(2-Cyano-2-(phenyl or naphthyl)-2-substituted-ethyl) pyrazines, pyrimidines and pyridazines Application No.** EP1988300222A, **Filed:**19880112 , **Published:** 19880803 **EP276920 A1**

Popular Press

Quoted in the following articles**:**

The Vibrant Philly Biotech Scene: Focus on Computer-aided Drug Design and Gfree Bio, LLC, PharmaceuticalIntellegence.com.
http://pharmaceuticalintelligence.com/2015/02/10/the-vibrant-philly-biotech-scene-focus-on-computer-aided-drug-design-and-gfree-bio-llc/

Chemistry By The Numbers, C&E News, September 9, 2013, Volume 91, Issue 36, page 51-55. http://cen.acs.org/articles/91/i36/Chemistry-Numbers.html

Bill Gates Takes Stake in Creating New Drugs Wall Street Journal, April 29, 2010
http://online.wsj.com/article/SB10001424052748703648304575212431415129588.html

Leveling the field. Future Pharmaceuticals podcast and article, 2009. Chuck Reynolds, Research Fellow Johnson & Johnson, speaks with Don Janezic, Business Development Manager Fujifilm Lifesciences, about the current state of fragment-based drug design (link no longer active).

Pharma's Road Ahead, C&E News, June 19, 2006, Volume 84, issue 25, page 56-78. http://pubs.acs.org/cen/pharma/8425sciencetext.html

Drugs by Design, C&E News**,** November 28, 2005, Volume 83, issue 48, page 28-30.
http://pubs.acs.org/isubscribe/journals/cen/83/i48/html/8348sci1.html

Elite Team Draws Bead on Molecular Design, Industrial Chemical News, 1986, Vol. 7, 5-6.